Jonathon Keats

Jonathon Keats, Hong Kong, 2012 Jonathon Keats (born October 2, 1971) is an American conceptual artist and experimental philosopher known for creating large-scale thought experiments. Keats was born in New York City and studied philosophy at Amherst College. He now lives in San Francisco and Italy. Provided by Wikipedia
Showing 1 - 8 results of 8 for search 'Jonathan Keats', query time: 0.03s Refine Results
  1. 1
    Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway

    Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway by Enze Liu, Nathan Becker, Parvathi Sudha, Chuanpeng Dong, Yunlong Liu, Jonathan Keats, Gareth Morgan, Brian A. Walker

    Published 2023-01-01
    Get full text
    Article
  2. 2
    Molecular mechanisms of bortezomib resistant adenocarcinoma cells.

    Molecular mechanisms of bortezomib resistant adenocarcinoma cells. by Erika Suzuki, Susan Demo, Edgar Deu, Jonathan Keats, Shirin Arastu-Kapur, P Leif Bergsagel, Mark K Bennett, Christopher J Kirk

    Published 2011-01-01
    Get full text
    Article
  3. 3
    Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases.

    Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases. by Zarko Manojlovic, Austin Christofferson, Winnie S Liang, Jessica Aldrich, Megan Washington, Shukmei Wong, Daniel Rohrer, Scott Jewell, Rick A Kittles, Mary Derome, Daniel Auclair, David Wesley Craig, Jonathan Keats, John D Carpten

    Published 2017-11-01
    Get full text
    Article
  4. 4
    Structural variants shape the genomic landscape and clinical outcome of multiple myeloma

    Structural variants shape the genomic landscape and clinical outcome of multiple myeloma by Cody Ashby, Eileen M. Boyle, Michael A. Bauer, Aneta Mikulasova, Christopher P. Wardell, Louis Williams, Ariel Siegel, Patrick Blaney, Marc Braunstein, David Kaminetsky, Jonathan Keats, Francesco Maura, Ola Landgren, Brian A. Walker, Faith E. Davies, Gareth J. Morgan

    Published 2022-05-01
    Get full text
    Article
  5. 5
    Daratumumab induces CD38 internalization and impairs myeloma cell adhesion

    Daratumumab induces CD38 internalization and impairs myeloma cell adhesion by Jayeeta Ghose, Domenico Viola, Cesar Terrazas, Enrico Caserta, Estelle Troadec, Jihane Khalife, Emine Gulsen Gunes, James Sanchez, Tinisha McDonald, Guido Marcucci, Balveen Kaur, Michael Rosenzweig, Jonathan Keats, Steven Rosen, Amrita Krishnan, Abhay R Satoskar, Craig C Hofmeister, Flavia Pichiorri

    Published 2018-10-01
    Get full text
    Article
  6. 6
    UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition

    UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition by Teresa Ezponda, Daphné Dupéré-Richer, Christine M. Will, Eliza C. Small, Nobish Varghese, Tej Patel, Behnam Nabet, Relja Popovic, Jon Oyer, Marinka Bulic, Yupeng Zheng, Xiaoxiao Huang, Mrinal Y. Shah, Sayantan Maji, Alberto Riva, Manuela Occhionorelli, Giovanni Tonon, Neil Kelleher, Jonathan Keats, Jonathan D. Licht

    Published 2017-10-01
    Get full text
    Article
  7. 7
    CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma

    CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma by Hadas Lewinsky, Emine G. Gunes, Keren David, Lihi Radomir, Matthias P. Kramer, Bianca Pellegrino, Michal Perpinial, Jing Chen, Ting-fang He, Anthony G. Mansour, Kun-Yu Teng, Supriyo Bhattacharya, Enrico Caserta, Estelle Troadec, Peter Lee, Mingye Feng, Jonathan Keats, Amrita Krishnan, Michael Rosenzweig, Jianhua Yu, Michael A. Caligiuri, Yosef Cohen, Olga Shevetz, Shirly Becker-Herman, Flavia Pichiorri, Steven Rosen, Idit Shachar

    Published 2023-07-01
    Get full text
    Article
  8. 8
    Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.

    Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. by Patricia M LoRusso, Aleksandar Sekulic, Jeffrey A Sosman, Winnie S Liang, John Carpten, David W Craig, David B Solit, Alan H Bryce, Jeffrey A Kiefer, Jessica Aldrich, Sara Nasser, Rebecca Halperin, Sara A Byron, Mary Jo Pilat, Scott A Boerner, Diane Durecki, William P D Hendricks, Daniel Enriquez, Tyler Izatt, Jonathan Keats, Christophe Legendre, Svetomir N Markovic, Amy Weise, Fatima Naveed, Jessica Schmidt, Gargi D Basu, Shobana Sekar, Jonathan Adkins, Erica Tassone, Karthigayini Sivaprakasam, Victoria Zismann, Valerie S Calvert, Emanuel F Petricoin, Leslie Anne Fecher, Christopher Lao, J Paul Eder, Nicholas J Vogelzang, Jane Perlmutter, Mark Gorman, Barbara Manica, Lisa Fox, Nicholas Schork, Daniel Zelterman, Michelle DeVeaux, Richard W Joseph, C Lance Cowey, Jeffrey M Trent

    Published 2021-01-01
    Get full text
    Article

Search Tools: